Bausch + Lomb Corporation
BLCO Healthcare Medical Instruments & Supplies
Bausch + Lomb Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 6.47% from fiscal 2024.
- Revenue
- +7.34%
- EPS
- +222.4%
- Free cash flow
- +182.5%
- Total debt
- +2.93%
Quarter to September 2026, against a year earlier
Follow BLCO
Alert me
Bausch + Lomb Corporation 10-Q filed Oct 28, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 29, 2026: 13 added · 7 removed · 63 modified; 36 with only figures updated
-
Modified · split · OVERVIEW
Bausch + Lomb understandsWe understand that BHC continues tobelieve that completing the Separation, which may include the monetization of all or a portion of BHC’s ownership interest in Bausch + Lomb, the sale of the Company (a “Sale Transaction”), the transfer of all or a portion of BHC’s remaining direct or indirect equity interest in Bausch + Lomb to its shareholders (the “Distribution”), or a combination thereof, makes strategic sense and that BHC continues toevaluate all relevant factors and considerationsrelatedrelating tocompleting the Separation, including those factors describedits investment inBHC’s public filings. The Distribution is subject to the achievement of targeted debt leverage ratios and the completion of the Separation is subject to the receipt of any applicable shareholder and other necessary approvals and other factors and is subject to various risk factors. There can be no assurance that the Separation will be consummatedBausch + Lomb,the formincluding anysuch consummated Separation would take or that a Distribution or Sale Transaction will occur as partcompletion ofthat Separation or that even if consummated, we will realizetheanticipated benefits from thefull Separation.For additional information on the risks related to the SeparationHowever,see Item 1A. “Risk Factors — Risks Relating to the Separation” of our Annual Report. Therethere can be no assurance that the Separation will be consummated, the form any such consummated Separation would take or thata Distribution or Sale Transaction will occur as part of that Separation or that, even if consummated, we will realize the anticipated benefits from the Separation.